Correlation Between Checkpoint Therapeutics and Bio Path

Can any of the company-specific risk be diversified away by investing in both Checkpoint Therapeutics and Bio Path at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Checkpoint Therapeutics and Bio Path into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Checkpoint Therapeutics and Bio Path Holdings, you can compare the effects of market volatilities on Checkpoint Therapeutics and Bio Path and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Checkpoint Therapeutics with a short position of Bio Path. Check out your portfolio center. Please also check ongoing floating volatility patterns of Checkpoint Therapeutics and Bio Path.

Diversification Opportunities for Checkpoint Therapeutics and Bio Path

-0.5

Correlation Coefficient

Checkpoint Therapeutics  Bio Path

Very good diversification

The 3 months correlation between Checkpoint and Bio is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Checkpoint Therapeutics and Bio Path Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bio Path Holdings and Checkpoint Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Checkpoint Therapeutics are associated (or correlated) with Bio Path. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bio Path Holdings has no effect on the direction of Checkpoint Therapeutics i.e., Checkpoint Therapeutics and Bio Path go up and down completely randomly.

Pair Corralation between Checkpoint Therapeutics and Bio Path

Given the investment horizon of 90 days Checkpoint Therapeutics is expected to generate 0.47 times more return on investment than Bio Path. However, Checkpoint Therapeutics is 2.11 times less risky than Bio Path. It trades about -0.12 of its potential returns per unit of risk. Bio Path Holdings is currently generating about -0.14 per unit of risk. If you would invest  354.00  in Checkpoint Therapeutics on October 22, 2024 and sell it today you would lose (36.00) from holding Checkpoint Therapeutics or give up 10.17% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Checkpoint Therapeutics  vs.  Bio Path Holdings

Checkpoint Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Bio Path Holdings

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Bio Path Holdings are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, Bio Path demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Checkpoint Therapeutics and Bio Path

The main advantage of trading using opposite Checkpoint Therapeutics and Bio Path positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Checkpoint Therapeutics position performs unexpectedly, Bio Path can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will offset losses from the drop in Bio Path's long position.

The idea behind Checkpoint Therapeutics and Bio Path Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.